AZOPT Drug Patent Profile
✉ Email this page to a colleague
When do Azopt patents expire, and what generic alternatives are available?
Azopt is a drug marketed by Sandoz and is included in one NDA.
The generic ingredient in AZOPT is brinzolamide. There are eleven drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the brinzolamide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Azopt
A generic version of AZOPT was approved as brinzolamide by WATSON LABS INC on November 27th, 2020.
Summary for AZOPT
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 96 |
Patent Applications: | 2,069 |
Drug Prices: | Drug price information for AZOPT |
What excipients (inactive ingredients) are in AZOPT? | AZOPT excipients list |
DailyMed Link: | AZOPT at DailyMed |
Pharmacology for AZOPT
Drug Class | Carbonic Anhydrase Inhibitor |
Mechanism of Action | Carbonic Anhydrase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for AZOPT
US Patents and Regulatory Information for AZOPT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sandoz | AZOPT | brinzolamide | SUSPENSION/DROPS;OPHTHALMIC | 020816-001 | Apr 1, 1998 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for AZOPT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sandoz | AZOPT | brinzolamide | SUSPENSION/DROPS;OPHTHALMIC | 020816-001 | Apr 1, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
Sandoz | AZOPT | brinzolamide | SUSPENSION/DROPS;OPHTHALMIC | 020816-001 | Apr 1, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
Sandoz | AZOPT | brinzolamide | SUSPENSION/DROPS;OPHTHALMIC | 020816-001 | Apr 1, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for AZOPT
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Novartis Europharm Limited | Azopt | brinzolamide | EMEA/H/C/000267 Azopt is indicated to decrease elevated intraocular pressure in:ocular hypertension;open-angle glaucomaas monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues. |
Authorised | no | no | no | 2000-03-09 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for AZOPT
See the table below for patents covering AZOPT around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
New Zealand | 237754 | SUBSTITUTED THIOPHENE SULPHONAMIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING INTRAOCULAR PRESSURE | ⤷ Try a Trial |
Netherlands | 300098 | ⤷ Try a Trial | |
Germany | 10299054 | ⤷ Try a Trial | |
Japan | 2562394 | ⤷ Try a Trial | |
Australia | 655924 | ⤷ Try a Trial | |
Netherlands | 300389 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for AZOPT
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0527801 | SPC/GB03/004 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: BRINZOLAMIDE; REGISTERED: CH IKS 55236 19991217; UK EU/1/00/129/01 20000309; UK EU/1/00/129/02 20000309 |
0527801 | CA 2009 00014 | Denmark | ⤷ Try a Trial | |
0527801 | CA 2002 00030 | Denmark | ⤷ Try a Trial | |
0527801 | C300098 | Netherlands | ⤷ Try a Trial | PRODUC NAME: BRINZOLAMIDUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; NATL. REGISTRATION NO/DATE: EU/1/00/129/01-02 20000309; FIRST REGISTRATION: CH IKS 55236 19991217 |
0527801 | 3/2003 | Austria | ⤷ Try a Trial | PRODUCT NAME: BRINZOLAMIDUM; NAT. REGISTRATION NO/DATE: EU/1/00/129/01-02 20000309; FIRST REGISTRATION: LI 55236 19991217 |
0527801 | 91555 | Luxembourg | ⤷ Try a Trial | 91555, EXPIRES: 20160403 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |